COVID-19. U07.1 - COVID-19
Conditions
Interventions
Intervention 1: Intervention group: On the first day, 1600 mg of Favipiravir BD, and on the second to fifth day, 600 mg of Favipiravir BD and concurrent hydroxychloroquine, 400 mg BD on the first da
Sponsors
Quality Improvement of Intensive Care Research Center- Shahid Beheshti University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: a- Respiratory Rate(RR)=30 /min b- SpO250% e- Diagnosis confirmed by CPR or CT scan f- Age more than 18 years
Exclusion criteria
Exclusion criteria: a- G6PD Deficiency b- QT interval more than 450 milliseconds c- myasthenia gravis d- Pregnancy- Breast Feeding e- Severe Renal or Hepatic Failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| No fever for 3 days. Timepoint: Daily. Method of measurement: Medical Records.;- SpO2>93%. Timepoint: daily. Method of measurement: Medical Records.;CXR observation. Timepoint: After the end of the treatment period. Method of measurement: Observation. | — |
Secondary
| Measure | Time frame |
|---|---|
| - All cause Mortality. Timepoint: once. Method of measurement: Medical Records.;- Need to Mechanical ventilation. Timepoint: Daily. Method of measurement: Medical Records.;Drug Adverse Effect. Timepoint: Daily. Method of measurement: Medical Records. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mohammad Fathi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed